Dean: School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. August 2018 to date.

 Dean: School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. August 2017 to 2018.

Principal Investigator: Severe Malaria A Research and Trials (SMAART) consortium: A prospective observational malaria study. March 2020 to date.

Co-Investigator: Austere Environments Consortium for Enhanced Sepsis Outcome (ACESO) study. July 2016 to date.

Co-Investigator: Austere Environments Consortium for Enhanced Sepsis Outcome (ACESO) study. July 2016 to date.

Co-Principal Investigator: Phase III randomized, open, controlled study to evaluate the immune response to the hepatitis B antigen of the RTS,S/AS01E candidate vaccine, when administered as primary vaccination integrated into an EPI regimen to infants living in sub-Saharan Africa programme. June 2012 to date.

Principal Investigator: Multiple Micronutrient Study in women living in the Barekese sub-district of the Ashanti Region. An International Collaboration with University of Utah-United States of America (USA),   Kirk Humanitarian-USA and Kwame Nkrumah University of Science and Technology. August 2013 to 2017.

Co-Principal Investigator: Phase 3 double-blind, randomized efficacy and safety comparison of prasugrel and placebo in pediatric patients with sickle cell disease. April 2014 to 2017.

Principal Investigator: Comparative, Open Label, Dose and Regimen Optimization Follow-up Study of Intravenous and Intramuscular Artesunate in African Children with Severe Malaria. July 2011 to July 2014.

Principal Investigator: RTS,S Phase III Project Extension. A phase III, double blind (observer-blind), randomized, controlled multi-center study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa. May 2011 to June 2014.

Principal Investigator: An epidemiological study to assess Plasmodium falciparum parasite prevalence and serological conversion rates in catchment areas of a Phase III trial of the candidate malaria vaccine RTS,S/AS01E in sub-Saharan Africa. March 2011 to June 2014.

Principal Investigator: A multi-center, observer blind, participant blind, randomized, controlled, Phase III study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa. August 2009 to April 2014.

Senior Clinical Investigator: MalariaGEN (Malaria Genomic Epidemiological Network). Sponsored by Bill and Melinda Gates Foundation. November 2006 to 2010.

Senior Clinical Investigator: A Phase II randomized, controlled, partially-blind study of the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals candidate Plasmodium falciparum vaccines RTS,S/AS02D and RTS,S/AS01E, when administered IM according to one of three dose schedules in children aged 5 to 17 months living in Ghana. June 2006 to 2008.

 Clinical Trial Monitor: World Health Organization (WHO)/Tropical Disease Research (TDR). December 2005 to 2015.